Approximately, 15% of confirmed coronavirus disease-19 (COVID-19) patients develop a severe disease, leading to complications including pneumonia, acute respiratory distress syndrome, respiratory failure, shock, organ failure and potentially death. The leading mediators of lung injury in COVID-19 patients are the pro-inflammatory cytokines produced during virus infection in the lungs. Therefore, early detection of pro-inflammatory cytokines in confirmed COVID-19 patients could provide important information about disease progression and inform appropriate early intervention. The overall goal of this project is to determine the type and levels of pro-inflammatory cytokines in oropharyngeal swabs taken from suspected COVID-19 patients.